SG Americas Securities LLC Has $5.40 Million Position in Cencora, Inc. $COR

SG Americas Securities LLC lowered its holdings in Cencora, Inc. (NYSE:COR) by 65.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,265 shares of the company’s stock after selling 33,102 shares during the quarter. SG Americas Securities LLC’s holdings in Cencora were worth $5,396,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Norges Bank bought a new stake in shares of Cencora in the 2nd quarter valued at approximately $695,215,000. Artisan Partners Limited Partnership bought a new position in shares of Cencora during the 2nd quarter worth approximately $411,888,000. Vanguard Group Inc. boosted its stake in Cencora by 5.3% in the 2nd quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock valued at $6,740,340,000 after buying an additional 1,125,661 shares in the last quarter. Viking Global Investors LP grew its position in Cencora by 95.0% in the second quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after acquiring an additional 1,013,913 shares during the period. Finally, Ameriprise Financial Inc. grew its position in Cencora by 228.6% in the second quarter. Ameriprise Financial Inc. now owns 974,505 shares of the company’s stock valued at $292,207,000 after acquiring an additional 677,952 shares during the period. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Down 0.0%

Shares of NYSE COR opened at $335.73 on Friday. Cencora, Inc. has a 12-month low of $233.61 and a 12-month high of $377.54. The firm’s 50-day simple moving average is $349.89 and its 200 day simple moving average is $318.27. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32. The company has a market cap of $65.13 billion, a price-to-earnings ratio of 42.23, a price-to-earnings-growth ratio of 1.60 and a beta of 0.66.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. During the same period in the previous year, the firm posted $3.34 earnings per share. The company’s revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were given a $0.60 dividend. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, November 14th. This represents a $2.40 annualized dividend and a yield of 0.7%. Cencora’s dividend payout ratio is presently 30.19%.

Insider Activity at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of the company’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the transaction, the chief executive officer directly owned 37,940 shares in the company, valued at approximately $12,398,792. This represents a 11.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of the firm’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the transaction, the executive vice president directly owned 18,796 shares in the company, valued at $6,484,620. This trade represents a 8.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 20,317 shares of company stock worth $7,009,260 over the last 90 days. Insiders own 10.80% of the company’s stock.

Wall Street Analysts Forecast Growth

COR has been the subject of a number of analyst reports. JPMorgan Chase & Co. lifted their price objective on Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Wall Street Zen cut shares of Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. Mizuho lifted their price target on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Barclays began coverage on shares of Cencora in a research note on Monday, December 8th. They set an “overweight” rating and a $400.00 price objective on the stock. Finally, TD Cowen raised their price objective on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, November 10th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, Cencora currently has an average rating of “Moderate Buy” and an average target price of $379.50.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.